Latest Cell signaling Stories
WELWYN GARDEN CITY, England and BOSTON, January 7, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced they have signed an agreement with Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases. Under the terms of the...
Jackson Laboratory researchers led by Associate Professor Zhong-wei Zhang, Ph.D., have provided direct evidence that a specific neurotransmitter receptor is vital to the process of pruning synapses in the brains of newborn mammals. Faulty pruning at this early developmental stage is implicated in autism-spectrum disorders and schizophrenia. The definitive evidence for N-methyl-D-aspartate receptor (NMDAR) in pruning has eluded researchers until now, but in research published in the...
The ability of the eye of a fruit fly (Drosophila melanogaster) to respond to light depends on a delicate ballet that keeps the supply of light sensors called rhodopsin constant as photoreceptors turn on and off in response to light exposures, said researchers from Baylor College of Medicine (www.bcm.edu) and the Jan and Dan Duncan Neurological Research Institute (http://www.nri.texaschildrens.org/) at Texas Children's Hospital in an article that appears online in the journal PLOS Biology...
BOCA RATON, Fla., Dec. 5, 2012 /PRNewswire/ -- Dr. David Zava, President of ZRT Laboratory, a testing and research facility specializing in individualized hormone tests, appears on The SUZANNE Show this week to talk about an innovative way to whip your hormones back into shape! Make sure to tune in Wednesday, December 5, at 7:00 am (ET/PT) as they air on Lifetime Television. Many people think hormonal imbalance just means "menopause" or "periomenopause"-- that's really the tip of the...
Using a super-resolution fluorescent microscope, medical scientists are a step closer to understanding why and how human immune cells decide to activate or not, thus enabling or preventing disease taking hold in the body. Professor Katharina Gaus and her team at the Centre for Vascular Research based at UNSW’s Lowy Cancer Research Centre used some of the most advanced super-resolution optical microscope technology available anywhere in the world to see changes in individual proteins in...
Researchers at the University of Geneva, Switzerland, demonstrate that the receptors that bind the toxin of this bacterium control how cell division is oriented Anthrax uses a receptor on the surface of cells to inject its lethal toxins. However, the physiological function of this receptor, named Anthrax Toxin Receptor 2a (Antxr2a), remained unknown until now. A team led by Marcos Gonzalez-Gaitan, a professor at the University of Geneva (UNIGE), Switzerland, in collaboration with Gisou van...
MIAMI, Nov. 19, 2012 /PRNewswire/ -- AAG Health & Wellness, a recognized leader in hormone replacement therapy for men, is excited to announce the release of a video that follows the trials and tribulations of a client over the course of his first six month hormone treatment plan. (Photo: http://photos.prnewswire.com/prnh/20121119/FL15499 ) Watch: Harvey's story. His hormone therapy experience. The video's subject is a 61 year Miami Beach executive named Harvey who turns to...
SEATTLE, Nov. 15, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that GPR17-targeting compounds, which were previously identified by Omeros in connection with unlocking this orphan receptor, have now been demonstrated to promote differentiation of the cells that form myelin in the central nervous system. Myelin is critical for the proper functioning of the nervous system, and demyelination is associated with multiple nervous system disorders, including...
INDIANAPOLIS, Nov. 9, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the annual meeting of the American College of Rheumatology (ACR), which takes place Nov. 10-14, 2012, in Washington, D.C. These compounds include tabalumab, an anti-BAFF monoclonal antibody, and baricitinib, a janus kinase (JAK) inhibitor being developed in partnership with Incyte Corporation. The...
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Ambit Biosciences Inc. today announced that the company has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib. Existing investor OrbiMed Advisors led the financing with participation from other existing Ambit investors including Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV,...
